{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-001348","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2026-10-15T20:18:27+00:00","discovered_at":"2026-10-15T20:19:00.443448+00:00","generated_at":"2026-10-15T20:19:06.023459+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anavex gets FDA clearance of Fragile X IND for blarcamesine; Phase 2a in ~60 adults planned","bullets":["FDA notified Anavex on Oct 15, 2026 that it may proceed with its blarcamesine IND for Fragile X syndrome; the IND is now open for U.S. clinical study.","Planned Phase 2a trial ANAVEX2-73-FXS-001: randomized, double-blind, placebo-controlled, dose-ranging oral solution in ~60 adult males with FXS.","Primary endpoints are safety, tolerability and pharmacokinetics; secondary endpoints include Aberrant Behavior Checklist-FXS (ABC-FXS) and NIH Toolbox cognition.","Anavex now holds open INDs in all three core indications: Alzheimer's disease, Rett syndrome and Fragile X syndrome; blarcamesine has FDA Orphan Drug Designation in FXS.","Sept 2026 Frontiers in Pharmacology study reported 14 days of oral blarcamesine produced dose-related EEG biomarker improvements in Fmr1 knockout mice; no FDA-approved FXS treatment exists."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-001348","json":"https://secwatch.observer/filing/0001731122-26-001348.json","markdown":"https://secwatch.observer/filing/0001731122-26-001348.md","text":"https://secwatch.observer/filing/0001731122-26-001348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001348/0001731122-26-001348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001348/e8009_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-15T20:19:06.023459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}